CorMedix (NASDAQ: CRMD) reported Q2 EPS of $0.28, $0.12 better than the analyst estimate of $0.16. Revenue for the quarter came in at $39.7 million versus the consensus estimate of $33.06 million.

For earnings history and earnings-related data on CorMedix (CRMD) click here.